Please assess the completion status of the following clinical trial:

Trial Title: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion criteria:~* Males and Females aged ≥ 18 years (≥ 12 years in PART C) with PVNS or GCTTS with, at least, one measurable site of disease on MRI.~* Patients expected to get surgery (PART A of study only).~* Vital signs within the ranges: systolic blood pressure 80-150 mmHg , diastolic blood pressure 50-100 mmHg, pulse rate 40-100 bpm, oral body temperature 35.0-37.5°C.~* Patients with normal level of serum ionized calcium and phosphate.~* Women of child-bearing potential must use highly effective contraception during the study and for 84 days after the study drug infusion.~Exclusion criteria:~* Patients with major surgery less than 3 months prior to start study drug or who have still side effects of such therapy.~* Presence of systemic illness precluding definitive surgery or increasing the risk to patients due to potential immunosuppression.~* Use previously of intra-articular treatment within 4 weeks prior dosing.~* Patients with dermal change indicative of lymphedema or phlebolymphedema. disease.~* Patients with elevated troponin T and/or CK levels (\> 1.5 x ULN for the laboratory) or with history of myositis, rhabdomyolysis or other myopathic disease.~* Patients receiving immunosuppressive treatment as well as corticosteroids which cannot be discontinued at least 4 weeks before dosing.~* Patients engaged in a resistance exercise training program.~* Patients with pacemakers or any metallic objects as exclusion for MRI~* Patients with concomitant disease know to get influence on bone metabolism~* Patients who have history of drug or alcohol abuse within 12 months prior study dosing.~* Pregnant or nursing (lactating) women.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MCS110 (Type: EXPERIMENTAL): Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
- MCS110 3 mg/kg (Type: EXPERIMENTAL): Part C: MCS110 3 mg/kg (i.v. infusion)
- MCS110 5 mg/kg (Type: EXPERIMENTAL): Part C: MCS110 5 mg/kg (i.v. infusion)
- MCS110 10 mg/kg (Type: EXPERIMENTAL): Part C: MCS110 10 mg/kg (i.v. infusion)
- MCS110 3 mg/kg & MCS110 10mg/kg (Type: EXPERIMENTAL): Part C: MCS110 3 mg/kg (i.v. infusion) \& MCS110 10 mg/kg (i.v. infusion)
- MCS110 5 mg/kg & MCS110 10mg/kg (Type: EXPERIMENTAL): Part C: MCS110 5 mg/kg (i.v. infusion) \& MCS110 10 mg/kg (i.v. infusion)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete